Valius Health, Inc. provides comprehensive cancer diagnostic and tumor profiling services for patients and oncologists. The company analyzes tumor DNA, RNA, and proteins to identify actionable therapeutic targets and treatment options.
Subscribe to see Valius Health, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Valius Health, Inc. is a healthtech company headquartered in United States. Its most recent funding round raised $9.7M in March 2026. Xcout tracks 7 named people at Valius Health, Inc., including Edward Larkin (Chief Executive Officer). Xcout recorded 3 job postings from Valius Health, Inc. in the last 90 days.
As of 16 November 2026. Source: Xcout Intel.
1 more named person on record for Valius Health, Inc., with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $9.7M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Xcout recorded 3 job postings from Valius Health, Inc. in the last 90 days, from a hiring record Xcout has kept since September 2026.
The weekly hiring trend, the roles and locations behind it — see Valius Health, Inc.'s hiring signals →
A few of Valius Health, Inc.'s closest competitors — see the full list of competitors and alternatives →
Lab Angelus, Inc. builds digital infrastructure and coordination platforms that connect community pathology laboratories with molecular reference laboratories for precision oncology. Its flagship product, LabDispatch, streamlines cancer specimen logistics and testing workflows to help patients receive timely molecular profiling and targeted treatments.
Person Health Inc. provides a preventive health-intelligence platform that combines differentiated diagnostics, person-centered data, and guided engagement to help clinicians and researchers recognize health risks earlier. Its initial focus is a research-use-only program centered on breast cancer detection using blood-based molecular fingerprinting, with plans to expand to non-invasive breath technologies and other diseases.
Hedera Dx is headquartered in Epalinges, Switzerland, and provides hospital in-house laboratories with a full suite of next-generation sequencing genomic profiling solutions, including FFPE and ctDNA testing for modern cancer care.
Molecular You offers an advanced biomarker testing and analysis platform designed to provide a comprehensive, single-test health assessment approach.
Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is a company dedicated to accelerating the commercialization of diagnostic solutions. It offers global pharmaceutical companies comprehensive data, advanced analytics, and implementation support. Central to its operations is the DXRX platform. This platform features DXRX data solutions, providing access to extensive diagnostic testing data pipelines from a broad network of laboratories, including real-time DXRX signal alerts, lab and physician mapping, and a testing dashboard. The DXRX platform also hosts a marketplace where laboratories, pharmaceutical firms, and diagnostic companies can connect to collaborate on precision medicine diagnostics. Diaceutics further provides DXRX Patient Journey, a tool for pharmaceutical clients to conduct detailed longitudinal analyses of individual patient biomarker testing paths, helping identify opportunities for earlier intervention and treatment. DXRX Lab Benchmarking allows laboratories to sharpen their competitive edge by comparing their key criteria against industry counterparts, encompassing metrics such as disease focus, testing methodologies, market share, turnaround times, and their standing as leaders in specific diagnostic fields. The DXRX Test Reimbursement service assists pharma clients in funding novel companion diagnostics, thereby shortening the time required for their widespread adoption. Furthermore, DXRX Test Signal delivers immediate notifications of testing events, empowering pharmaceutical clients to swiftly identify therapeutically actionable patients. Beyond the platform, Diaceutics furnishes services for diagnostic landscape analysis, strategic planning, implementation, and ongoing tracking, alongside expert consulting tailored to precision medicine diagnostics. Its extensive service portfolio also covers test standardization, quality evaluations, optimization of test reports, technical laboratory support, assistance with test access and reimbursement, laboratory training, and various educational resources.
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Valius Health, Inc.? Suggest a correction · Work at Valius Health, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.